Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Timeline At The Top: What Witty Did At GSK

This article was originally published in Scrip

Executive Summary

Sir Andrew Witty has announced his intention to retire as CEO of GlaxoSmithKline PLC in March 2017. Having joined as a graduate trainee in 1985, he became CEO in 2008. Eight years is a long time to head up a big pharma company, and while Sir Andrew's detractors might argue that he has failed to deliver shareholder value, none can argue that it has been for lack of action. Here is a timeline of major events at GSK since the start of his tenure at the top.

You may also be interested in...



Lilly BioMedicines Head Ricks Tasked With Overseeing Growth Phase As Next CEO

Long-time CEO John Lechleiter, who led the company through a challenging period of enormous patent expirations, will step down at year's end.

2Q Preview: GSK, Bayer, Celgene, Amgen, AZ, BMS, Sanofi, Merck, Abbvie

GSK, Bayer, Celgene, Amgen, AstraZeneca, Bristol-Myers Squibb, Sanofi, Merck & Co and AbbVie are among the pharma companies due to report second-quarter results imminently. As the financial reporting season moves into a second week, Scrip takes a look at the key things to watch for.

What’s On CEO Andrew Witty’s To-Do List Before Exiting GSK

The company showed signs of stabilization in the first quarter, as Witty insisted his diversified strategy is beginning to pay off. But a new CEO will have to contend with the potential entry of Advair generics.

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC064766

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel